Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC)
- PMID: 19926549
- DOI: 10.2478/v10042-009-0091-2
Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC)
Abstract
The epigenetic inactivation of tumor suppressor genes may play an important role in the development and progression of many cancer types, including lung cancer. Therefore, we investigated the association between the aberrant promoter methylation of 2 genes: the Death-Associated Protein Kinase (DAPK) and the Ras Association Domain Family 1A (RASSF1A) by using methylation-specific PCR, and the clinicopathological features and prognosis in 70 radically resected non-small cell lung cancers (NSCLCs). Hypermethylation of the DAPK and RASSF1A promoters was found in 24 (34%), and in 18 (26%) tumor DNA samples, respectively. Regarding different clinicopathological features of NSCLCs, the DAPK promoter methylation was more frequently observed in squamous cell carcinoma (46%) than in adenocarcinoma (25%) and large cell carcinoma (22%), but there were no significant statistical differences (p=0.3). On the other hand, a statistically significant trend was observed between the RASSF1A methylation and a histological type of tumor (p=0.06). 45% of adenocarcinoma tumors showed RASSF1A promoter methylation in comparison to 17% of squamous cell carcinomas and 22% of large cell carcinomas. When both markers were analyzed according to the tumor-node-metastasis (TNM) staging system, no statistically significant differences were observed between stage I, II and IIIa, and the DAPK (p=0.2) and RASSF1A methylation (p=0.1). In comparison, when stage I and II were grouped together and considered vs. stage IIIa, a significant association between RASSF1A methylation and the TNM was found (p=0.03). The group of patients with tumors showing DAPK promoter methylation had significantly poorer overall survival rates (p=0.02) than the patients with tumors that did not show DAPK promoter methylation. However, the association between the RASSF1A promoter methylation status and the overall survival rates was not statistically significant (p=0.48). In conclusion, this paper supports the importance of epigenetic gene regulation in lung cancer progression and prognosis.
Similar articles
-
Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers.BMC Cancer. 2007 May 3;7:74. doi: 10.1186/1471-2407-7-74. BMC Cancer. 2007. PMID: 17477876 Free PMC article.
-
Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.Lung Cancer. 2007 Oct;58(1):131-8. doi: 10.1016/j.lungcan.2007.05.011. Epub 2007 Jul 2. Lung Cancer. 2007. PMID: 17606310
-
Inactivation of RASSF1A, RARbeta2 and DAP-kinase by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma.Cancer Biol Ther. 2009 Mar;8(5):444-51. doi: 10.4161/cbt.8.5.7686. Epub 2009 Mar 21. Cancer Biol Ther. 2009. PMID: 19221469
-
The tumor suppressor RASSF1A in human carcinogenesis: an update.Histol Histopathol. 2005 Apr;20(2):645-63. doi: 10.14670/HH-20.645. Histol Histopathol. 2005. PMID: 15736067 Review.
-
The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis.Carcinogenesis. 2011 Mar;32(3):411-6. doi: 10.1093/carcin/bgq266. Epub 2010 Dec 14. Carcinogenesis. 2011. PMID: 21156971
Cited by
-
Association between promoter methylation of DAPK gene and HNSCC: A meta-analysis.PLoS One. 2017 Mar 1;12(3):e0173194. doi: 10.1371/journal.pone.0173194. eCollection 2017. PLoS One. 2017. PMID: 28249042 Free PMC article.
-
Epigenetic regulation in lung cancer.MedComm (2020). 2023 Oct 26;4(6):e401. doi: 10.1002/mco2.401. eCollection 2023 Dec. MedComm (2020). 2023. PMID: 37901797 Free PMC article. Review.
-
Pre-clinical lung squamous cell carcinoma mouse models to identify novel biomarkers and therapeutic interventions.Front Oncol. 2023 Sep 25;13:1260411. doi: 10.3389/fonc.2023.1260411. eCollection 2023. Front Oncol. 2023. PMID: 37817767 Free PMC article. Review.
-
DNA methylation and apoptosis resistance in cancer cells.Cells. 2013 Jul 18;2(3):545-73. doi: 10.3390/cells2030545. Cells. 2013. PMID: 24709797 Free PMC article.
-
The significance of epigenetic alterations in lung carcinogenesis.Mol Biol Rep. 2013 Jan;40(1):309-25. doi: 10.1007/s11033-012-2063-4. Epub 2012 Oct 20. Mol Biol Rep. 2013. PMID: 23086271 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources